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Objective—Deleted in malignant brain tumors 1 (DMBT1) belongs to the scavenger receptor cysteine-rich superfamily of
proteins and is implicated in innate immunity, cell polarity, and differentiation. Here we studied the role of DMBT1 in
endothelial cells.
Methods and Results—DMBT1 was secreted into the extracellular matrix (ECM) by endothelial cells in vitro and in situ
and the presence of DMBT1 in the ECM increased endothelial cell adherence. Endothelial cell-derived DMBT1
associated with galectin-3 (coprecipitation), and human recombinant DMBT1 bound EGF, vascular endothelial growth
factor and Delta-like (Dll) 4 (specific ELISAs). Compared to cells from wild-type mice, endothelial cells from
DMBT1/ mice demonstrated reduced migration, proliferation, and tube formation. In vivo recovery from hindlimb
ischemia was attenuated in DMBT1/ animals as was vascular endothelial growth factor -induced endothelial
sprouting from isolated aortic rings; the latter response could be rescued by the addition of recombinant DMBT1. The
Notch pathway is involved in multiple aspects of vascular development, including arterial-venous differentiation and we
found that endothelial cells from DMBT1/ mice expressed more EphrinB2 than cells from wild-type mice. Levels of
Dll1, Dll4, Hes1, Hey1, and EphB4, on the other hand, were decreased.
Conclusion—Taken together, the results of this study indicate that DMBT1 functions as an important endothelium-
derived ECM protein that is able to bind angiogenic factors and promote adhesion, migration, proliferation, and
angiogenesis as well as vascular repair. Mechanistically, DMBT1 interacts with galectin-3 and modulates the
Notch signaling pathway as well as the differential expression of ephrin-B2 and EphB4. (Arterioscler Thromb
Vasc Biol. 2012;32:442-448.)
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The mechanisms that regulate angiogenesis and vasculardifferentiation are complex but include interactions be-
tween the endothelium and the extracellular matrix (ECM).1
Human deleted in malignant brain tumors 1 (DMBT1; also
known as lung glycoprotein-340) is a secreted high molecular
weight pattern recognition molecule belonging to the scav-
enger receptor cysteine-rich superfamily that binds polyphos-
phorylated and -polysulfated structures found on bacterial
and viral surfaces as well as in the ECM. As its name suggests
the DMBT1 gene was presumed to play a role in tumor
suppression,2 however it now seems that DMBT1 may play a
more complex role in tumorigenesis than originally thought
and that its actions differ from that of a conventional tumor
suppressor gene.3
DMBT1 is expressed by several cell types and the polym-
erization of hensin, the rabbit orthologue of DMBT1, and its
interaction in the ECM with galectin-3 reportedly modulates
the polarity of epithelial cells.4 The molecular mechanisms
involved are unclear but the activation of integrin v1
triggers the secretion of hensin into the ECM where it
polymerizes, binds integrin 6, and stimulates cell differen-
tiation.5 Integrins with a 1 subunit are receptors for ECM
proteins, such as the laminins and fibronectin, and play an
important role in angiogenesis.6 Given that DMBT1 has been
detected in/on endothelial cells in samples from patients,7 it is
tempting to suggest a link between integrin-induced DMBT1
deposition and angiogenesis. The aim of the present study
was therefore to assess the expression of DMBT1 in the
endothelium and to determine its role in angiogenesis and
vascular repair.
Materials and Methods
A detailed description of all of the materials, antibodies and standard
methods used appear in Supplemental Materials and Methods,
available online at http://atvb.ahajournals.org.
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Animals
Male wild-type and DMBT1/ mice (C57BL/6 background),8 were
bred at the central animal facility at the German Cancer Research
Center Heidelberg. All animal experiments were approved by the
Regierungspra¨sidium Karlsruhe (license G172-09).
Hindlimb Ischemia
Hindlimb ischemia was induced as outlined.9 Limb perfusion was
measured with a laser Doppler imager every three to four days (Moor
Instruments Ltd, Millwey, England). After 14 days the mice were
killed and the M. adductor and M. semimembranosus were removed
for analysis.
Aortic Ring Assay
Aortae from wild-type and DMBT1/ mice were removed, cleaned,
and embedded in a collagen gel (collagen type I, BD Biosciences,
Heidelberg, Germany) in a 48-well plate containing MCDB 131
medium (Gibco/Invitrogen, Karlsruhe, Germany) supplemented with
murine serum (2.5%) from the donor animals. After 24 hours, murine
vascular endothelial growth factor (VEGF) (30 ng/mL) and/or
human recombinant DMBT1 (100 ng/mL) were added and the
tube-like structures were allowed to develop over 7 days. Thereafter,
the samples were fixed (4% paraformaldehyde) and endothelial cells
were visualized using antibodies against CD31.
Cell Culture
Murine endothelial cells from wild-type and DMBT1/ mice and
human umbilical vein endothelial cells were isolated and cultured as
described previously.10 Murine endothelial cells were used up to
passage 9 while first passage human endothelial cells were used
throughout. The use of human material in this study conforms to the
principles outlined in the Declaration of Helsinki and the isolation of
endothelial cells was approved by the ethic committee at the Goethe
University.
Statistics
Data are expressed as the meanSEM, and statistical evaluation was
performed using Student t-test for unpaired data, 1-way ANOVA
followed by a Bonferroni t-test, or ANOVA for repeated measures
Figure 1. Deleted in malignant brain tumors 1 (DMBT1) is pres-
ent in the ECM surrounding endothelial cells in vivo. A, DMBT1
(blue) in capillaries (lectingreen) and small arteries
(-actinred) in skeletal muscle. B, Localization of DMBT1 (red)
with the filipodia extended by tip cells (green) in the developing
retina (P5). C, En face preparations of partially endothelium-
intact (E) and -denuded (E) aorta from a wild-type (WT) and
DMBT1/ mouse. CD31blue, DMBT1red, -actingreen.
The bars represent (A) 50 and (B, C) 20 m, respectively.
Figure 2. Expression of deleted in malignant brain tumors 1
(DMBT1) in cultured endothelial cells and interaction with
galectin-3. A, DMBT-1 expression in cultured human umbilical
vein endothelial cells. DMBT1red, galectin-3green,
DAPIblue. B, Coimmunoprecipitation (IP) of DMBT1 and
galectin-3 from human endothelial cells, pc indicates positive
control. Identical results were obtained in 2 additional experi-
ments each using a different cell batch.
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where appropriate. Values of P0.05 were considered statisti-
cally significant.
Results
Localization and Regulation of DMBT1 in
Endothelial Cells
To determine the vascular localization of DMBT1 we com-
pared its expression with that of endothelial (FITC-lectin) and
smooth muscle cell (-actin) markers in murine tissues. In the
hindlimb adductor muscle; DMBT1 surrounded muscle fibers
and was detected in close proximity to capillary endothelial
cells as well as small arteries (Figure 1A). In the developing
retina (postnatal day 5) DMBT1 was detected at the leading
edge of the capillary network and was closely associated with
the filipodia that extended from tip cells. DMBT1 was also
evident in the stalk cells of the retina where it seemed to be
adjacent to, rather than within, the endothelium (Figure 1B),
a finding consistent with the fact that DMBT1 is a secreted
protein. In en face preparations of the murine aorta, DMBT1
was detected when the endothelium was intact but not once
the endothelial layer was removed mechanically, indicating
the endothelial association of the protein (Figure 1C). No
DMBT1 was detected in samples from DMBT1/ mice
(Figure 1C and Supplementary Figure I).
Primary cultures of human umbilical vein endothelial cells
expressed DMBT1; low levels were detected in the cell
cytosol with the majority of the protein being in the ECM
(Figure 2A). Consistent with the fact that it is highly
glycosylated, DMBT1 was detected by Western blotting as a
diffuse 340 kDa band. Galectin-3, which interacts with
DMBT1 in other tissues to promote DMBT1 polymeriza-
tion,11 was also expressed by the endothelium,12 and could be
coprecipitated with DMBT1 from confluent cultures of hu-
man endothelial cells and vice versa (Figure 2B).
Effect of DMBT1 on Endothelial Cell Adhesion
The effect of DMBT1 on endothelial cell adhesion and migra-
tion was studied using DMBT1-containing and -depleted ECM
generated by wild-type or DMBT1/ lung endothelial cells.
This procedure was chosen in preference to plating cells on
human recombinant DMBT1 (hrDMBT1) as the native pro-
tein is highly glycosylated, a modification that affects its
function including its association with galectin-3.13 In the
endothelial cells plated onto DMBT1-containing ECM, pax-
illin and phosphorylated focal adhesion kinase (FAK) colo-
calized in clusters at the cell membrane. However, in cells
plated onto DMBT1-deficient ECM, phosphorylated FAK
was only detected close to the nucleus (Figure 3A). More-
over, fewer endothelial cells adhered to the DMBT1-depleted
ECM (Figure 3B).
The function of DMBT1 was further addressed by deter-
mining the attachment of cells to culture dishes coated with
hrDMBT1. Endothelial cells adhered to hrDMBT1-coated
surfaces to a similar degree as to laminin- and fibronectin-
coated surfaces (Figure 3C). The dependency of hrDMBT1-
mediated cell adhesion on divalent cations (an index of
integrin-mediated cell adhesion) was similar to that of laminin
but less than that observed when cells were plated onto fibronec-
tin. Interestingly, endothelial cells from DMBT1/ mice dis-
played a significantly stronger adhesion to hrDMBT1, laminin,
and fibronectin in the presence but not in the absence of divalent
cations (Figure 3D, 3E). We found no significant difference in
the expression of v or 1 integrins in wild-type versus
DMBT1/ endothelial cells; however, the expression of 3
integrin was significantly lower in endothelial cells from
DMBT1/ mice (Supplementary Figure II).
Binding of hrDMBT1 to EGF, VEGF, and Dll4
Several ECM constituents are able to bind growth factors and
thus modulate angiogenesis. Because DMBT1 has a repetitive
structure with multiple binding sites we hypothesized that it
may also be able to sequester growth factors. Indeed,
hrDMBT1 was able to bind to EGF (Supplementary Figure
IIIA) and VEGF (Supplementary Figure IIIB). Moreover, we
also found that hrDMBT1 bound the Notch ligand Delta-like
Figure 3. Role of deleted in malignant brain tumors 1 (DMBT1) in endothelial cell adhesion. A, Intracellular localization of paxillin and
phosphorylated FAK (pFAK) in wild-type endothelial cells adhering to ECM generated by wild-type (WT) (DMBT1) and DMBT1/ cells
(DMBT1). Paxillingreen, pFAKred, phalloidinblue. B, Adhesion of wild-type endothelial cells to the DMBT1 or DMBT1 ECM.
C, Adhesion of wild-type endothelial cells to human recombinant DMBT1 (hrDMBT1), laminin (Lam), and fibronectin (Fib) in the pres-
ence of Ca2/Mg2 or EDTA. D, E, Adhesion of WT and DMBT1/ endothelial cells to ECM proteins; (D) in the presence of Ca2/
Mg2 and (E) in presence of EDTA. The bar graphs represent data obtained using 3 different cell batches; *P0.05, **P0.01.
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4 (Dll4; Supplementary Figure IIIC). Because all of these
factors are involved in angiogenesis it is feasible that their
association with DMBT1 can effectively increase their local
concentrations thus promoting the vascular response. The
latter interactions were disturbed by heparan sulfate (Supple-
mentary Figure IIID).
Role of DMBT1 in Endothelial Cell Migration and
Angiogenesis In Vitro
We next compared the ability of endothelial cells from
wild-type and DMBT1/ mice to migrate in a scratch-
wound assay as well as to proliferate and form tube-like
structures. Although wild-type endothelial cells migrated to
cover approximately 50% of the wound area after 22 hours,
the migration of endothelial cells from DMBT1/ mice was
markedly delayed (Supplementary Figure IVA). Moreover,
although endothelial cells from wild-type mice proliferated
well in the presence of 20% FCS, responses were attenuated
in cells from Dmbt1/ mice (Supplementary Figure IVB)
without any detectable increase in apoptosis.
The attenuated endothelial cell proliferation and migration
were also reflected in an impaired ability to form tube-like
structures on Matrigel in response to VEGF (Figure 4A). This
phenomenon was not restricted to endothelial cells in culture
as the formation of endothelial cell (CD-31 positive) capillary
sprouts was also attenuated in aortic rings from DMBT1/
mice following either incubation with solvent or VEGF
(Figure 4B). In a rescue experiment we next determined
whether or not the addition of hrDMBT1 could restore
responsiveness to VEGF. Recombinant DMBT1, either alone
or in combination with VEGF, slightly enhanced sprouting in
rings from wild-type mice (Figure 4B). In aortic rings from
DMBT1/ mice, hrDMBT1 alone was without significant
effect but it did restore responsiveness to VEGF to levels
similar to that observed in wild-type tissue.
Role of DMBT1 in Angiogenesis In Vivo
Next we determined the ability of DMBT1/ mice to
recover from hindlimb ischemia. This model seemed partic-
ularly appropriate because DMBT1 was detected in skeletal
muscle capillaries. In wild-type animals, femoral artery liga-
tion compromised hindlimb blood flow (laser Doppler mea-
surements), which recovered to approximately 75% of preli-
gation values within 14 days. Although limb perfusion was
comparable in wild-type and DMBT1/ mice prior to
ligation, blood flow in the ischemic limb recovered more
slowly with a maximal recovery of only 25% after 2 weeks
(Figure 5A). This correlated with the impaired vasculariza-
tion (arterial and capillary numbers) of the M. adductor in
hindlimbs from dmbt1/ mice (Figure 5B).
DMBT1 and Notch Signaling
Notch signaling plays a crucial role in reparative angiogene-
sis and changes in the expression of the Notch ligands, Dll1
and Dll4, have been reported to occur during postischemic
angiogenesis.14,15 Given that hrDMBT1 was able to bind
Dll4, we assessed the consequences of DMBT1 deletion on
the expression of components of the Notch signaling cascade.
Although Notch1 expression was slightly increased in
DMBT1/ endothelial cells (Figure 6A), the expression of
the ligands Dll1 and Dll4 mRNA was attenuated as was the
expression of Hes1 and Hey1, 2 downstream effectors of the
Notch signaling cascade.
The Notch pathway is involved in multiple aspects of
vascular development, including arterial-venous differentia-
tion, therefore we determined the consequences of DMBT1-
deletion on the expression of ephrin-B2 and EphB4, 2
proteins differentially expressed in arterial and venous endo-
thelium, respectively.16 Murine lung microvascular endothe-
lial cells expressed both ephrin-B2 and EphB4 but whereas
EphB4 levels were consistently higher in wild-type than in
DMBT1/ cells, the reverse was true for ephrin-B2 (Figure
6B). Similarly, decreased levels of EphB4 were detected in
vivo in skeletal muscle capillaries (Figure 6C). Moreover,
while coating mouse lung endothelial cells onto hrDMBT1
had no effect on EphB4 levels, it increased EphB4 levels in
DMBT1/ cells (Figure 6D).
Figure 4. Defective angiogenesis in endothelial cells from
deleted in malignant brain tumors 1 (DMBT1)/ mice. A, In
vitro tube formation on Matrigel by lung endothelial cells from
wild-type (WT) and DMBT1/ mice in the absence or presence
of murine vascular endothelial growth factor (VEGF) (50 ng/mL).
B, Endothelial cell sprouting (visualized using antibodies against
CD31) from aortic rings from wild-type and DMBT1/ mice
embedded in a collagen gel containing either solvent or murine
VEGF (30 ng/mL) in the absence and presence of human
recombinant DMBT1 (100 ng/mL). The bar graphs represent
data obtained using 3 independent cell batches (each in dupli-
cate) or 4 animals per group; *P0.05, **P0.01 vs solvent,
§P0.05, §§P0.01 vs WT.
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Discussion
The results of the present investigation demonstrate that
DMBT1 is an important vascular ECM protein, promoting
endothelial cell adhesion, migration, proliferation and repar-
ative angiogenesis. To our knowledge, this is the first time
that a protein of the scavenger receptor cysteine-rich super
family has been linked to these processes. Although the
precise molecular mechanisms underlying these effects re-
main to be determined in detail, we found that DMBT1
interacts with galectin-3, EGF, VEGF, and Dll4. Moreover,
the genetic deletion of DMBT1 attenuates Notch signaling
and thus differentially affects the expression of ephrin-B2 and
EphB4.
Almost nothing is known about the vascular actions of
DMBT1. Immunohistochemical analysis of heart tissue pre-
viously revealed sporadic DMBT1 expression in/on endothe-
lial cells as well as in the heart valves of patients with
bacterial endocarditis7; which fits well with reports linking
DMBT1 with inflammation and innate immune responses in
different organs.17,18
Our data indicate that DMBT1 is secreted by endothelial
cells to the ECM under normal physiological conditions in
vitro and in vivo, and that human DMBT1 is similar to hensin
(rabbit DMBT1) with regard to its interaction with galectin-3,
a -galactoside-binding lectin. The interaction of the 2
proteins is likely to be required for their vascular effects as
not only does the deletion of DMBT1 attenuate angiogenesis
and vascular repair (present study) but galectin 3 inhibition
and downregulation also reduce VEGF- and basic fibroblast
growth factor-mediated angiogenesis in vitro, and angiogenic
responses are reduced in galectin-3/ animals.19 Mechanis-
tically, the angiogenic effects of galectin-3 have been attrib-
uted to binding; via its carbohydrate recognition domain, to
the GnTV synthesized N-glycans of integrin v3, to induce
its clustering.19 Although we did not address the direct
interaction of DMBT1 with integrins we did observe that the
expression of 3 integrin was attenuated in endothelial cells
from DMBT1/ mice. More recently galectin-3 was also
reported to modulate angiogenesis in human endothelial cells
by retaining the cell surface expression of the VEGF receptor
2.20 However, whether or not DMBT1 also affects VEGF
receptor cycling remains to be determined.
DMBT1 has a repetitive structure with 14 SRCR domains
and multiple binding sites making it likely that 1 molecule
DMBT1 binds a number of other molecules.21 Thus binding
to galectin-3 may not account for all of the effects of DMBT1
and its ability to bind EGF, VEGF, and Dll4 and may account
for some of its effects on angiogenesis and vascular repair.
This is of relevance as the interaction of growth factors with
the ECM is one key mechanism thought to regulate the
actions of growth factors, including VEGF.22 It is thus
tempting to speculate that interaction with DMBT1 may be a
means of increasing the local concentrations of angiogenic
growth factors. The results of the aortic ring assays indicate
Figure 5. Delayed recovery from hindlimb ischemia in deleted in
malignant brain tumors 1 (DMBT1) / mice. A, Hindlimb perfu-
sion in wild-type (WT) and dmbt1/ mice immediately and 14
days after ischemia. B, Capillary and arteriole density assessed
measured by immunofluorescence staining of the muscles in the
affected limb 14 days after ischemia induction. The bar graphs
represent data obtained using 8 animals per group; *P0.05,
**P0.01, ***P0.001 vs WT.
Figure 6. Deleted in malignant brain tumors 1 (DMBT1) and en-
dothelial cell signaling. A, Relative expression of mRNA encod-
ing components of the Notch signaling cascade (mRNA/trans-
ferrin receptor) in endothelial cells from wild-type (WT) and
DMBT1/ mice. B, Expression of ephrin-B2 and EphB4 in WT
and DMBT1/ endothelial cells. C, Expression EphB4 (cross-
section, red) and EphrinB2 (longitudinal section, blue) in skeletal
muscle from WT and DMBT1/ mice. D, Effect of DMBT1 (100
ng/mL, 12 hours) on the expression of EphB4 in cultured lung
endothelial cells from WT and DMBT1/ mice. The bar graphs
represent data obtained using 3 independent experiments each
using a different cell batch or 4 animals per group; *P0.05,
**P0.01 vs control or WT.
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that DMBT1 is required for normal responsiveness to VEGF
as the sprouting response to VEGF could be restored in
DMBT1/ vessels by the addition of VEGF and hrDMBT1
but not by hrDMBT1 alone. Interestingly, all of the growth
factors tested are glycosylated and contain disulfide bonds,
implicating that these characteristics might be involved in the
binding to DMBT1.18
The Notch ligand, Dll4, is upregulated in response to
hindlimb ischemia in mice and localized at the forefront of
sprouting capillaries.15 Functionally Dll4 is required for
angiogenesis and its inhibition by the intramuscular injection
of an adenovirus encoding the soluble form of Dll4 extracel-
lular domain precipitates the formation of a disorganized,
low-perfused capillary network in ischemic muscles.15 We
found that the deletion of DMBT1 elicited similar effects as
those described following Dll4 inhibition, ie, attenuated
capillary formation and markedly attenuated recovery of
blood flow in ischemic hindlimbs. Moreover, DMBT1 dele-
tion was found to have marked consequences on Notch
signaling. Indeed, compared to cells from wild-type mice,
endothelial cells from DMBT1/ mice showed attenuated
expression of the Notch regulated genes Hes1 and Hey1. To
further assess the link between DMBT1 and Notch signaling,
we studied the consequences of DMBT1 deletion on
ephrin-B2 and EphB4, 2 proteins that are involved in arterio-
venous differentiation and previously reported to be regulated
by Notch.14,16,23,24 Indeed, we observed that the deletion of
DMBT1 altered the expression of both markers, ie, decreased
EphB4 while increasing ephrin-B2 expression in murine lung
endothelial cells.
The fact that DMBT1 promotes angiogenesis and vascular
repair is at odds with the assumption—based on the function
of hensin and its presumed role in tumor suppression—that
DMBT1 might inhibit cell proliferation and initiate cell
differentiation. However, as mentioned previously, DMBT1
may play a more complex role in tumorigenesis than origi-
nally thought and that its actions differ from that of a
conventional tumor suppressor gene.3 It is also important to
remember that the vascular repair processes studied in the
hindlimb are not solely dependent on angiogenesis but also
on different subsets of cells of the hematopoietic lineage. The
latter promote the vascularization of matrix material and
tumors by acting as accessory cells secreting a number of
proangiogenic factors and differentiating to form new blood
vessels.25,26 This is of relevance as DMBT1 is upregulated in
stem/progenitor cells during regeneration4 and was proposed
as a bone marrow hepatic stem cell primer in rats subjected to
common bile duct ligation.27 It will be interesting to assess
whether or not DMBT1 is expressed in circulating progenitor
cells with angiogenic potential (previously referred to as
endothelial progenitor cells), or whether its expression affects
the recruitment of such cells to sites of injury. To date studies
on the role of DMBT1 on tumor development have focused
on nonvascular cells, but it remains to be determined to what
extent the lack of endothelial cell-derived DMBT1 (and
eventually decreased Notch signaling) can contribute to the
abnormal organization, structure and altered function (eg,
hyper-permeability and heterogeneous blood flow) of tumor
vasculature and eventually metastasis.
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Supplement Material  
Deleted in malignant brain tumors 1 (DMBT1) is present in the vascular extracellular 
matrix and promotes angiogenesis 
Materials and Methods 
Materials. Purified human recombinant DMBT1 was generated as described.1 The polyclonal 
anti-DMBT1p84 antibody used was raised against human DMBT1,2 the antibodies against 
galectin-3 and CD31 were from BD Biosciences (Heidelberg, Germany) the 3 integrin 
antibody from Epitomics (Burlingame, CA), and the v integrin antibody from Chemicon 
(Temecula,CA). The polyclonal anti-mouse EphB4 and ephrinB2 antibodies were from R&D 
Systems (Wiesbaden, Germany), the paxillin antibody from abcam (Cambridge, UK), the 
phospho-FAK (Y397) antibody and the Alexa Fluor 546 and Alexa Fluor 647 secondary 
antibodies from Invitrogen (Karlsruhe; Germany). EGF, VEGF and interferon- were from 
PeproTech (Hamburg, Germany) and hrDLL4 from R&D Systems (Wiesbaden, Germany). All 
other substances were from Sigma-Aldrich (Munich, Germany).  
Animals. Male wild-type and dmbt1-/- mice (C57BL/6 background),2 were bred at the central 
animal facility at the German Cancer Research Center Heidelberg. All animal experiments 
were approved by the Regierungspräsidium Karlsruhe (license G172-09). 
Cell Culture. Murine endothelial cells from wild-type and dmbt1-/- mice and human umbilical 
vein endothelial cells were isolated and cultured as described previously.3 Murine endothelial 
cells were used up to passage 9 while first passage human endothelial cells were used 
throughout. The use of human material in this study conforms to the principles outlined in the 
Declaration of Helsinki and the isolation of endothelial cells was approved by the ethic 
committee at the Goethe University. 
Adhesion Assays. Endothelial cells from wild-type and dmbt1-/- mice were allowed to 
deposit their ECM on a 96-well plate while being cultured with DMEM/F12 containing 20% 
FCS for five to six days. After washing with PBS the adherent cells were removed by 
washing with Triton X-100 (1% v/v) in PBS containing protease inhibitors (1 mmol/L 
phenylmethylsulfonyl fluoride and 2 mmol/L N-ethylmaleimide) leaving the deposited matrix 
on the plastic surface. Wells were then washed with PBS and BSA (0.1%) to block non-
specific adhesion before endothelial cells from wild-type mice were seeded in the presence 
of either Ca2+/Mg2+ (1 mmol/L each) or EDTA (5 mmol/L). Adherent cells where washed with 
warm PBS, fixed by the addition of 70% ethanol and incubated with crystal violet (0.2%, 30 
minutes). Samples were then incubated in ethanol overnight and adherence determined with 
an ELISA reader at 560 nm. In separate experiments the wells were coated with hrDMBT1, 
laminin or fibronectin and the adhesion of endothelial cells from wild-type and dmbt1-/- mice 
was analyzed.. 
Immunohistochemistry. Skeletal muscle: Cryo-sections were stained using muscles 
imbedded in Tissue Tek (Sakura, Heppenheim, Germany). After fixation in phosphate buffer 
(100 mmol/L, pH 7.3) containing 4% formalin samples were blocked with 5% goat serum and 
permeabilized with 0.5% Triton X-100 followed by incubation with lectin-B4-FITC and anti -
smooth muscle actin-Cy3.  
Aorta: Perivascular tissue was removed; aortae were cut into rings and pinned with the 
endothelial cell surface facing upwards. The endothelial cells on one side of each preparation 
were removed by scraping and then washed carefully with sterile Hank´s solution. 
Thereafter, samples were fixed, permeabilized and incubated with antibodies as described.4 
Retina: Frozen eyes from 5 day old mice were fixed in phosphate buffer (100 mmol/L, pH 
7.3) containing 4% formalin (overnight 4°C). Thereafter, the retina was isolated, washed and 
permeabilized as described.5 Endothelial cells were visualized using lectin-B4-FITC.  
Endothelial cells: Human endothelial cells cultured on glass coverslips were fixed in 4% 
paraformaldehyde, permeabilized with Triton X-100 (0.03%) and incubated with appropriate 
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antibodies as outlined in the result section. The samples were viewed and images analyzed 
using a confocal microscope (LSM 510 META, Zeiss) and Axiovision software. 
Immunoprecipitation and Immunoblotting. Endothelial cells were lysed and DMBT1 or 
galectin-3 were immunopreciptated with the appropriate antibodies. Triton X-100-soluble 
proteins or immunoprecipitates were heated with SDS-PAGE sample buffer, separated by 
SDS-PAGE and specific proteins were detected as described.3 
Proliferation, Migration and Tube Formation Assays. Primary cultures of murine 
endothelial cells were seeded on 24 well plates (40000 cells/well) coated with fibronectin. 
After 72 and 96 hours culture in DMEM/F12 medium (Gibco/Invitrogen, Karlsruhe, Germany) 
with 20% FCS and 0.4% ECGS-H (Promocell, Heidelberg, Germany), the cells were 
trypsinized and counted (Casy 1 TT, Schärfe System, Reutlingen, Germany).  
Endothelial cell migration was assessed using culture inserts with a 500 µm cell-free 
barrier (ibidi, Martinsried, Germany). Once cells reached confluence the FCS and ECGS-H 
content was reduced to 25% and the culture insert removed. Endothelial cell migration was 
monitored over 24 hours and the distance migrated was calculated using Axiovision software 
(Zeiss, Jena, Germany). It should be noted that the migration of murine lung endothelial cells 
was much slower than that of the human umbilical vein endothelial cells generally used in 
such assays.  
Tube formation was assessed using primary cultures of murine endothelial cells seeded 
onto microscope slides (µ-angiogenesis; ibidi, Martinsried, Germany) coated with Matrigel. 
Cells were cultured in DMEM/F12 containing 25% of the usual concentration of FCS and 
ECGS-H and in the absence and presence of murine VEGF (50 ng/mL). Tube formation was 
analyzed after four hours.  
Aortic Ring Assay. Aortae from wild-type and dmbt1-/- mice were removed, cleaned and 
embedded in a collagen gel (collagen type I, BD Biosciences, Heidelberg, Germany) in a 48 
well plate containing MCDB 131 medium (Gibco/Invitrogen, Karlsruhe, Germany) 
supplemented with murine serum (2.5%) from the donor animals. After 24 hours murine 
VEGF (30 ng/mL) was added and the tube-like structures allowed to develop over 7 days. 
Thereafter, the samples were fixed (4% paraformaldehyde) and endothelial cells were 
visualized using antibodies against CD31.  
Hindlimb Ischemia. Hindlimb ischemia was induced as outlined 6. Limb perfusion was 
measured with a laser Doppler imager every three to four days (Moor Instruments Ltd, 
Millwey, England). After 14 days the mice were killed and the M. adductor and M. 
semimembranosus were removed for analysis.  
RT-qPCR. Total RNA was isolated from cultured mouse endothelial cells. Random 
hexanucleotide primers (Promega, Mannheim, Germany) were used for reverse transcription 
of the RNA. The cDNA was used for quantitative PCR using following primers: Notch 1 
forward: 5´-CCTCAGATGGTGCTCTGATG-3´, reverse: 5´-CTCAGGTCAGGGAGAACTAC-
3´; Dll1 forward: 5´-CATCCGATACCCAGGTTGTC-3´, reverse: 5´-
ACGGCTTATGGTGAGTACAG-3´; Hes1 forward: 5´-GAGGCGAAGGGCAAGAATAAA-3´, 
reverse: 5´-GTGGACAGGAAGCGGGTCA-3´; Hey1 forward: 5´-
TGAGCTGAGAAGGCTGGTAC-3´, reverse: 5´-ACCCCAAACTCCGATAGTC-3´. The primer 
for the transferrin receptor (Assay ID: Mm00441941_m1) and for dll4 (Assay ID: 
Mm00444619_m1) were from Applied Biosystems (Darmstadt, Germany). The transferrin 
receptor was used as reference gene. 
ELISA for Binding of hrDMBT1 to EGF, VEGF and DLL4. Microtiter plates (Greiner Bio-
One, Frickenhausen, Germany) were coated with human recombinant EGF, VEGF or DLL4 
in serial 1:2 dilutions in carbonate buffer overnight. After washing with Tris-buffered saline 
including 0.1% (v/v) Tween 20 (TBS-T), the plates were incubated with a 0.4 nmol/L solution 
of hrDMBT1 and 2 mmol/L Ca2+ for 40 minutes at room temperature. After washing with TBS-
T the DMBT1-specific monoclonal mouse antibody Hyb213-06 (1:5000; Antibodyshop, 
Gentofte, Denmark) was added, followed by a horseradish peroxidase-conjugated anti-
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mouse antibody (Chemicon International, Temecula, California, USA). The bound enzyme 
was detected by adding TMB-substrate solution (125 µg/mL 3,3`,5,5`-Tetramethyl-benzidine; 
125 µg/mL (Sigma-Aldrich) in 0.1 mol/L citrate buffer pH 4.5 with 0.05 % (v/v) H2O2. After 
incubation for 20 minutes, the reaction was stopped with 2 mol/L HCl and the intensity of the 
dye reaction at 450 nm was analyzed with an ELISA reader. As control, wells without 
hrDMBT1 incubation were used. 
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